{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.105","value":"2.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"description":"Time to response was defined as the time from treatment initiation to the first documentation of response.","dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEAN","populationDescription":"Safety Analysis Set: All participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 6 months","title":"Time To Response","type":"SECONDARY","unitOfMeasure":"months"}